- Investing Ideas
- Swedish Pharmaceuticals & Biotech Healthy high growth potential
Swedish Pharmaceuticals & Biotech Healthy high growth potential
Results
6
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
6 companies
Camurus
Market Cap: SEK 35.9b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 601.50
7D
-3.5%
1Y
-9.8%
Bonesupport Holding
Market Cap: SEK 15.1b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 222.60
7D
3.6%
1Y
-31.1%
BioArctic
Market Cap: SEK 27.8b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BIOA B
SEK 315.20
7D
-2.3%
1Y
41.6%
Genovis AB (publ.)
Market Cap: SEK 1.3b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 19.10
7D
-5.7%
1Y
-26.5%
Moberg Pharma
Market Cap: SEK 455.9m
A pharmaceutical company, develops and commercializes medical products primarily in Sweden.
MOB
SEK 9.56
7D
-2.3%
1Y
4.7%
AlzeCure Pharma
Market Cap: SEK 852.2m
Operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system.
ALZCUR
SEK 6.30
7D
-0.6%
1Y
70.3%